

AWMSG Scrutiny Panel confirms medicine fulfils an identified clinical need or offers benefit to the NHS in Wales

↓ YES

AWMSG assessment required*

↓ NO

AWMSG assessment not required *

Scrutiny Panel determines whether **full HTA**, **interim HTA** or **limited assessment** required based on defined criteria**

FULL HEALTH TECHNOLOGY ASSESSMENT (HTA)

- Likely to have significant impact to the NHS in Wales (service and/or budget) **and**;
- Not on the NICE TA/HST work programme **or**;
- The commercial arrangement as part of the NICE advice is not applicable to the NHS in Wales

Most likely to be medicines which are newly licensed or have significant new licence extensions

INTERIM HEALTH TECHNOLOGY ASSESSMENT (HTA)

- Likely to have significant impact to the NHS in Wales (service and/or budget) **and**;
- There's a delay in NICE advice[†] **and**;
- There's no suitable alternative licensed medicine available that will meet the patient's needs **and/or**;
- Further evidence/data needs collecting to strengthen a submission for full HTA **and/or**;
- There is a commercial arrangement for the NHS in Wales

LIMITED ASSESSMENT

- No anticipated service impact to the NHS in Wales **and**;
- Not on the NICE TA/HST work programme **and**;
- Likely to have small net budgetary impact or cost-saving to the NHS in Wales **and/or**;
- Included in national guidelines or accepted as standard of care **and/or**;
- Commissioned elsewhere in the UK **and/or**;
- Offers significant benefit in terms of service delivery or patient experience

Evidence evaluation and recommendation by the Licensed One Wales Medicines Assessment Group (LOWMAG)

Endorsement by the All Wales Medicines Strategy Group (AWMSG) followed by ratification by Welsh Government

*Scrutiny Panel decisions will be communicated back to the submitter who will have 10 working days to raise any objections regarding the decision

** The Scrutiny Panel may instruct that an assessment is conducted using information in the public domain if the MA holder does not engage

† There may be occasions when AWMSG will consider a medicine with NICE terminated appraisal status or a NICE negative recommendation